Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277409 | 0.86 | MAPK13 (0.52) | PDK2MAPK13MAPK14ADRA2AADRA1A | |
| SCHEMBL380772 | 0.77 | MAPK13 (0.76) | MAPK13MAPK14 | |
| SCHEMBL3279748 | 0.77 | HSD11B1 (0.41) | MAPK13MAPK14HSD11B1SCN9AFLT3 | |
| SCHEMBL3277809 | 0.76 | MAPK14 (0.42) | MAPK13MAPK14 | |
| SCHEMBL3278461 | 0.75 | CDK8 (0.40) | MAPK13MAPK14ADRA2AADRA1AKDR | |
| SCHEMBL379993 | 0.74 | MAPK13 (0.79) | MAPK13MAPK14 | |
| SCHEMBL379882 | 0.73 | MAPK13 (0.78) | MAPK13MAPK14 | |
| SCHEMBL14210404 | 0.71 | PDK2 (0.53) | PDK2 | |
| SCHEMBL3025015 | 0.69 | FGFR3 (0.49) | FLT3KDR | |
| SCHEMBL13702375 | 0.68 | HDAC8 (0.68) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | PDK2 347/4885MAPK13 37/4885MAPK14 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.